Immunohistochemical and Sequencing Analyses of the Wnt Signaling Components in Japanese Anaplastic Thyroid Cancers
Overview
Authors
Affiliations
We investigated the status of the components and target genes of the Wnt signaling pathway in Japanese anaplastic thyroid cancers (ATCs) in the present study. Nuclear and cytoplasmic positive staining of beta-catenin, which might indicate the existence of alterations in the Wnt signaling pathway, were found in 40.9% and 63.6% of the 22 ATC samples, respectively. The beta-catenin, adenomatous polyposis coli (APC) and Axin 1 gene mutations were observed in 4.5%, 9.0%, and 81.8% of the 22 ATC samples, respectively. Overexpression of cyclin D1 and c-myc, which are the target genes of the Wnt signaling pathway, was observed in 27.3% and 59.1% of the ATC samples, respectively. There was no significant correlation between nuclear or cytoplasmic positive staining of beta-catenin and nuclear positive staining of cyclin D1 or c-myc. Taken together, the results of beta-catenin immunohistochemistry suggest that alterations in the Wnt signaling pathway are associated with carcinogenesis of ATC, but the frequency of beta-catenin gene mutation in our series is lower than that previously reported. Furthermore, cyclin D1 and c-myc frequently accumulated in ATC, independently of dysfunction in the Wnt signaling pathway.
Tenascin-C Potentiates Wnt Signaling in Thyroid Cancer.
Hartmann H, Loberg M, Xu G, Schwarzkopf A, Chen S, Phifer C Endocrinology. 2025; 166(3).
PMID: 39951495 PMC: 11843548. DOI: 10.1210/endocr/bqaf030.
Wnt/β-catenin signaling is a therapeutic target in anaplastic thyroid carcinoma.
Diaz D, Bergdorf K, Loberg M, Phifer C, Xu G, Sheng Q Endocrine. 2024; 86(1):114-118.
PMID: 38806891 PMC: 11444896. DOI: 10.1007/s12020-024-03887-0.
Pires C, Saramago A, Moura M, Li J, Donato S, Marques I Int J Mol Sci. 2024; 25(4).
PMID: 38396644 PMC: 10888156. DOI: 10.3390/ijms25041966.
Saljooghi S, Heidari Z, Saravani M, Rezaei M, Salimi S J Clin Lab Anal. 2022; 37(1):e24804.
PMID: 36510340 PMC: 9833985. DOI: 10.1002/jcla.24804.
Thyroid Cancer and COVID-19: Prospects for Therapeutic Approaches and Drug Development.
Qu N, Hui Z, Shen Z, Kan C, Hou N, Sun X Front Endocrinol (Lausanne). 2022; 13:873027.
PMID: 35600591 PMC: 9114699. DOI: 10.3389/fendo.2022.873027.